The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease.

Wilfrid Mazier, Nicolas Saucisse, Blandine Gatta-Cherifi, Daniela Cota
Trends in Endocrinology & Metabolism. 2015-10-01; 26(10): 524-537
DOI: 10.1016/j.tem.2015.07.007

PubMed
Lire sur PubMed



1. Trends Endocrinol Metab. 2015 Oct;26(10):524-537. doi: 10.1016/j.tem.2015.07.007.

The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic
Disease.

Mazier W(1), Saucisse N(1), Gatta-Cherifi B(2), Cota D(3).

Author information:
(1)Institut National de la Santé et de la Recherche Médicale (INSERM),
Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, Unité 862,
33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie,
Physiopathologie de la Plasticité Neuronale, Unité 862, 33000 Bordeaux, France.
(2)Institut National de la Santé et de la Recherche Médicale (INSERM),
Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, Unité 862,
33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie,
Physiopathologie de la Plasticité Neuronale, Unité 862, 33000 Bordeaux, France;
Endocrinology Department, Haut-Lévêque Hospital, 33604 Pessac, France.
(3)Institut National de la Santé et de la Recherche Médicale (INSERM),
Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, Unité 862,
33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie,
Physiopathologie de la Plasticité Neuronale, Unité 862, 33000 Bordeaux, France.
Electronic address: .

The endocannabinoid system (ECS) functions to adjust behavior and metabolism
according to environmental changes in food availability. Its actions range from
the regulation of sensory responses to the development of preference for the
consumption of calorically-rich food and control of its metabolic handling. ECS
activity is beneficial when access to food is scarce or unpredictable. However,
when food is plentiful, the ECS favors obesity and metabolic disease. We review
recent advances in understanding the roles of the ECS in energy balance, and
discuss newly identified mechanisms of action that, after the withdrawal of first
generation cannabinoid type 1 (CB1) receptor antagonists for the treatment of
obesity, have made the ECS once again an attractive target for therapy.

Copyright © 2015 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.tem.2015.07.007
PMID: 26412154 [Indexed for MEDLINE]


Auteurs Bordeaux Neurocampus